ABSTRACT
OBJECTIVES:
Octreotide is a somatostatin analog, long-acting formulations of which have been used experimentally for the treatment of patients with invasive tumors and/or residual disease after conventional therapies. The objective of this retrospective study was to evaluate the efficacy of long-acting octreotide(Sandostatin LAR) for the treatment of thymic tumors, with a primary efficacy end point of progression-free survival.
METHODS:
Between 1994 and 2010, 44 patients with thymic malignancies were evaluated. Twenty-seven patients underwent an OctreoScan, and 12 OctreoScan-positive patients were treated with long-acting octreotideat a dose of 20 mg, given as an intramuscular injection, every 2 weeks.
RESULTS:
Treatment with long-acting octreotide gave the following results: 3 cases of partial response (25%), 5 cases of stable disease (42%), and 4 cases of progressive disease (33%), with an average progression-free survival of 8 months (range, 3 to 21). Treatment compliance and tolerability were good for all evaluated patients.
CONCLUSIONS:
The results of this study confirm the somatostatin receptor as a valid target for the treatment of thymic malignancies. Overall, therapy with long-acting somatostatin analogs seems to be safe and effective.
Efficacy and tolerability of long-acting octreotide in the treatment of thymic tumors: results of a pilot trial
Riferimento:
Am J Clin Oncol. 2012 Apr;35(2):105-9.
Autori:
Longo F, De Filippis L, Zivi A, Vitolo D, Del Signore E, Gori B, Diso D, Anile M, Venuta F, De Giacomo T, Coloni CF.
Fonte:
Am J Clin Oncol. 2012 Apr;35(2):105-9.
Anno:
2012
Azione:
Efficacia per octreotide a lunga durata d'azione (Sandostatina LAR) nel trattamento dei tumori timici.
Target:
Sandostatina LAR/tumori timici.
Sostanze:
